Lifting the Veil on Trichotillomania

Samuel R. Chamberlain, M.A.
Lara Menzies, B.A.
Barbara J. Sahakian, M.A., Ph.D.

“Dr. D,” a 32-year-old female general practitioner, presented to a psychiatric referral clinic with a history of repetitive hair pulling since age 14. Recently the hair pulling had escalated, and it now occupied 2–3 hours per day, usually during the evening when Dr. D was relaxing. Despite imaginative efforts to conceal her missing hair and eyebrows, Dr. D felt that she was “fighting a losing battle.” She reported an overpowering urge to touch, select, and pull out particular hairs and described feelings of tension that were only alleviated by the act of hair pulling. This behavior had led to a growing sense of frustration and shame and avoidance of social contact. When asked about her experience with hair pulling in her own medical practice, Dr. D replied that on numerous occasions she had asked patients with unusual scalp patches about deliberate hair pulling and that the patients invariably denied it.

What are the diagnostic issues in Dr. D’s case? What are the potential complications and comorbidities to look out for? What do we know about the neurobiology of this disorder? What treatment options are supported by the evidence? What are the key directions for future clinical and neuroscience research?

Scope of the Problem and Diagnostic Considerations

Trichotillomania is a poorly understood disorder characterized by repetitive hair pulling that leads to noticeable hair loss, distress, and social or functional impairment (1, 2). The peak age at onset is 12–13 years, and the disorder is often chronic and difficult to treat (3, 4). Hair pulling in early childhood (<5 years of age) can be regarded as a distinct clinical entity that tends to be self-limiting without the need for intervention (2, 5). Trichotillomania was first described in the literature over 100 years ago by French dermatologist Hallopeau. In DSM-IV, it is categorized as an impulse control disorder; diagnostic criteria are listed in Figure 1. Although rising tension and subsequent pleasure, gratification, or relief are integral to the current diagnostic criteria for trichotillomania, many people with debilitating hair pulling do not endorse these criteria (6, 7).

Trichotillomania is typically confined to one or two sites. It most frequently affects the scalp but can also involve the eyelashes, eyebrows, pubic hair, body hair, and facial hair (8). Patients tend to be highly secretive about the condition and to regard their behavior as shameful. Many hair pullers also exhibit additional stereotypic movements, such as nail biting, knuckle cracking, touching or playing with pulled hair, and hair eating (trichophagia) (6, 9). Along with the cosmetic and psychosocial consequences of the disorder, medical complications can occur, including infection, permanent loss of hair, repetitive stress injury, carpal tunnel syndrome (10), and gastrointestinal obstruction with bezoars as a result of trichophagia (11).

Epidemiology and Comorbidity

There have been no population-wide epidemiological studies of trichotillomania. In a survey of 2,500 college students, lifetime prevalence was estimated at 0.6% when strict DSM-III-R criteria were used (12). When the criteria were relaxed to exclude the items on sense of tension before hair pulling and gratification or relief afterward, pathological hair pulling was evident in 1.5% of males and 3.4% of females in the sample. In adult recruitment studies, female participants have typically outnumbered males by at least 3 to 1.

Trichotillomania is frequently linked with other conditions, notably mood and anxiety disorders. In a study of 60 adult hair pullers recruited from a trichotillomania clinic and newspaper advertisements (6), 82% had a past or current axis I diagnosis other than trichotillomania according to semistructured clinical interview. The highest reported lifetime prevalence estimates of comorbid disorders, occurring in >10% of the sample, were major depression, anxiety disorders (mainly generalized anxiety disorder...
and simple phobias), and substance use disorders; 23% of the sample met criteria for current major depression, and 10% for current obsessive-compulsive disorder (OCD). In a study of 15 younger patients with hair pulling (mean age=12 years) recruited from an outpatient clinic, nine met criteria for additional diagnoses, including attention deficit hyperactivity disorder (ADHD), tic disorder, OCD, and major depression (13).

Etiology

Hair pulling and related grooming phenomena frequently occur in family members of trichotillomania patients, and it is probable that multiple genes confer biological vulnerability (8). Zuchner and colleagues identified mutations in the Slit and Trk-like 1 (SLITRK1) gene in two trichotillomania subjects that were absent in more than 2,000 comparison subjects (14). This gene is associated with cortex development and neuronal growth, and rare mutations have also been associated with Tourette’s syndrome (15). Hemmings et al. (16) reported evidence for differences in distributions of serotonin 2A receptor genes between trichotillomania patients and comparison subjects. In animal work, Greer and Capecchi (17) reported that mice with mutation of the hoxb8 neurodevelopmental gene showed aberrant grooming behavior including hair pulling. Although preliminary, these data implicate polymorphisms in genes controlling brain development and neuromodulation in trichotillomania.

In some cases of trichotillomania, there is an apparent etiological role for stress; hair pulling can be seen as a soothing behavior that is driven by rising tension. Trichotillomania also shows unexpectedly high overlap with posttraumatic stress disorder (18), raising the possibility of additional affective contributions. Another school of thought emphasizes hair pulling as addictive or positively reinforcing insofar as it is associated with rising tension beforehand and relief afterward (19). However, for many patients, hair pulling is undertaken during times of relaxation and may in fact serve a self-stimulatory function (19). From a neurocognitive perspective, trichotillomania can be considered a habit disorder in which the sufferer is unable to exert sufficient top-down inhibitory control (20). Central to this model is the notion that the basal ganglia play a role in habit formation and that the frontal lobes are critical for normally suppressing or inhibiting such habits (20–22).

Trichotillomania and the Obsessive-Compulsive Spectrum

It has been proposed that certain conditions fall within an obsessive-compulsive spectrum, sharing overlapping clinical features, genetic contributions, and possibly treatment response (23, 24). Proposed members of this spectrum include OCD, trichotillomania, severe nail biting, compulsive skin picking, tic disorders, and eating disorders. Phenomenologically, trichotillomania is akin to OCD and many of these other conditions in that it is associated with irresistible urges to perform unwanted repetitive behavior (20). In a study by Richter and colleagues (25), OCD patients were found to have a greater lifetime occurrence of multiple spectrum conditions compared with panic disorder and social phobia patients. Higher than expected rates of trichotillomania, nail biting, and skin picking have also been found in relatives of OCD patients (26).

Several differences between trichotillomania and OCD have been noted, however (2, 5). Hair pulling is not usually driven by recurrent intrusive thoughts, whereas in OCD compulsions are frequently undertaken in response to obsessions. In comparison with OCD, trichotillomania has a younger peak age at onset, affects a greater proportion of females than males, and has lower rates of comorbidity (6, 8, 27). There may also be differences between trichotillomania and OCD in terms of neural dysfunction and cognitive profiles (discussed below).

“Dual treatment with behavioral therapy and an SSRI may provide advantages over monotherapy in some cases.”

Neuroimaging Dysfunction

Although caudate abnormalities have been observed in OCD, Stein et al. (28) found no evidence to support the existence of volumetric caudate abnormalities in subjects with trichotillomania. O’Sullivan et al. (29) found reduced left putamen volumes (part of the fronto-striatal motor circuit) in trichotillomania patients (medication status was not specified). Later, Stein et al. (30), using single photon emission computed tomography, found reduced neural activity in the left putamen and several frontal regions after 12 weeks of citalopram treatment in trichotillomania patients.

There is also evidence for involvement of the cerebellum in trichotillomania. A resting-state positron emission tomography study conducted by Swedo et al. (31) identified disproportionately increased brain metabolism in medication-free patients with trichotillomania in the cerebellum bilaterally and in the right superior parietal cortex. The relationship between these abnormalities and trichotillomania symptoms was difficult to evaluate, as metabolic rates correlated positively with trait (chronic) measures of anxiety but negatively with trichotillomania symptom severity. Evidence for cerebellar involvement has also been obtained in magnetic resonance imaging (MRI) studies. Keuthen and colleagues reported reduced volumes in this region in medication-free trichotillomania patients (32).

It is interesting to contrast these preliminary findings for trichotillomania, implicating regions such as the putamen and cerebellum, with findings in OCD, for which abnormalities have been reported in the orbitofrontal and anterior cingulate cortices and the caudate nucleus (20).
Collectively, these findings suggest some difference in the neural underpinnings of the two disorders, and this issue must be addressed in direct neuroimaging comparisons.

Structural MRI studies undertaken so far have used region-of-interest methods, which require that researchers select specific regions for volumetric analysis a priori. This approach is questionable given the paucity of data about the neurobiology of trichotillomania. Whole-brain analysis using techniques such as voxel-based morphometry may be useful in this regard. This unbiased automated approach allows for investigation of the whole brain for gray and white matter changes while taking into account multiple comparisons without the need for an a priori structural hypothesis. Functional neuroimaging studies using symptom provocation and exposure to symptom-relevant stimuli have been useful in OCD research (33) and could be applied to the study of trichotillomania.

Neurocognitive Dysfunction

Neuropsychological assessment is another useful tool for investigating neural dysfunction in trichotillomania and the disorder’s relationship with other obsessive-compulsive spectrum disorders. The problem of comorbidity confounds many cognitive studies of trichotillomania because a number of disorders, including depression, are themselves linked with cognitive dysfunction. Only a few studies have attempted to focus on “pure” cases of trichotillomania using hypothesis-driven tests. Recently, computerized assessment was used to compare cognition between patients with trichotillomania and no comorbid disorders, patients with OCD and no comorbid disorders, and healthy volunteers (34, 35). Both patient groups showed impaired impulse control, as measured with a stop-signal task. In the trichotillomania group, the impulse control deficit was especially severe and was correlated with symptom severity. Patients with OCD also showed cognitive inflexibility and executive dysfunction across several other neurocognitive tests, whereas trichotillomania patients did not, which suggests more restricted involvement of cortico-subcortical neural circuitry in trichotillomania. Stop-signal performance is dependent on the right inferior frontal gyrus (36, 37). In this light, the right inferior frontal gyrus and connected regions should be further investigated in neuroimaging studies of trichotillomania. The finding of markedly impaired response inhibition in trichotillomania (35) is reminiscent of findings in ADHD (38) and points toward a possible role for cognition-enhancing agents (39, 40, 41).

Treatment

Methods for assessing trichotillomania have varied widely among studies (7), and few objective validated clinical instruments have been developed. Examples include the Psychiatric Institute Trichotillomania Scale (42) and the Massachusetts General Hospital (MGH) Hair pulling Scale, which was derived from the Yale-Brown Obsessive Compulsive Scale and has good psychometric properties (43, 44).

Table 1 summarizes the published literature on treatment trials for trichotillomania. These studies have investigated a range of behavioral therapies and pharmacotherapies. Habit reversal, a behavioral therapy that has a longstanding tradition in the treatment of “nervous” habits and tics (58), involves training participants to undertake alternative, competing, harmless motor responses, such as fist clenching. In early work, Azrin and colleagues (45) conducted a nonblind trial with 34 trichotillomania patients (including four children) randomly assigned to either one session of habit reversal training or a time-matched session of individual negative practice—a technique involving grooming hair without pulling it out (two patients were not evaluated). Habit reversal was superior to negative practice training according to progress reports (rather than validated instruments) as early as day 1, and this difference remained significant at 4 weeks. Lerner and colleagues (50) conducted an uncontrolled evaluation of 9 weeks of behavioral therapy, including habit reversal, for trichotillomania patients. Treatment response was assessed with the Trichotillomania Impairment Scale and the Trichotillomania Severity Score. At immediate follow-up, significant improvements were noted in the patients who completed therapy, although these benefits were diminished at long-term follow-up.

A variety of drug treatments have also been investigated, including selective serotonin reuptake inhibitors (SSRIs) that are known to be effective for OCD (59). In a 5-week randomized double-blind crossover study, Swedo and colleagues (46) found that clomipramine was superior to the tricyclic desipramine in reducing trichotillomania symptoms in patients who completed treatment, as assessed with the Trichotillomania Impairment Scale, the Trichotillomania Severity Score, and physicians’ ratings of

**FIGURE 1. DSM-IV Criteria for Trichotillomania**

| A. Recurrent pulling out of one’s hair resulting in noticeable hair loss. |
| B. An increasing sense of tension immediately before pulling out the hair or when attempting to resist the behavior. |
| C. Pleasure, gratification, or relief when pulling out the hair. |
| D. The disturbance is not better accounted for by another mental disorder and is not due to a general medical condition (e.g., a dermatological condition). |
| E. The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning. |
### TABLE 1. Summary of Trichotillomania Clinical Treatment Trials, 1980–2006

<table>
<thead>
<tr>
<th>Study Author and Year</th>
<th>Design</th>
<th>Treatment and Number of Subjects Completing Treatment</th>
<th>Percent Female&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Age (years)&lt;sup&gt;ab&lt;/sup&gt;</th>
<th>Titration Range (Daily Dose)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azrin et al., 1980 (45)</td>
<td>Randomized assignment to one of two treatments</td>
<td>Single session of habit reversal therapy (18 patients) or negative practice training (14 patients)</td>
<td>71</td>
<td>28</td>
<td>—</td>
<td>Habit reversal treatment associated with significantly greater reductions in hair pulling episodes from day 1 onward; still clear at 4 weeks</td>
</tr>
<tr>
<td>Swedo et al., 1989 (46)</td>
<td>Randomized double-blind crossover design (non-placebo controlled)</td>
<td>2 weeks placebo, 5 weeks clomipramine, and 5 weeks desipramine (6 subjects) or 2 weeks placebo, 5 weeks desipramine, and 5 weeks clomipramine (7 subjects)</td>
<td>100</td>
<td>31.6</td>
<td>7.6</td>
<td>50–250 mg</td>
</tr>
<tr>
<td>Christenson et al., 1991 (47)</td>
<td>Randomized double-blind placebo-controlled crossover design</td>
<td>6 weeks fluoxetine, 5-week washout, 6 weeks placebo (8 subjects) or 6 weeks placebo, 5-week washout, 6 weeks fluoxetine (7 subjects)</td>
<td>93</td>
<td>31.6</td>
<td>6.2</td>
<td>20–80 mg</td>
</tr>
<tr>
<td>Streichenwein and Thornby, 1995 (48)</td>
<td>Randomized double-blind placebo-controlled crossover design</td>
<td>2-week placebo washout, 12 weeks fluoxetine, 5-week washout, 12 weeks placebo (8 subjects) or 2-week placebo washout, 12 weeks placebo, 5-week washout, 12 weeks fluoxetine (8 subjects)</td>
<td>88</td>
<td>39</td>
<td>12</td>
<td>20–80 mg</td>
</tr>
<tr>
<td>Stein et al., 1997 (49)</td>
<td>Open-label trial</td>
<td>12-week open-label trial of citalopram (13 subjects)</td>
<td>92</td>
<td>32.7</td>
<td>8.2</td>
<td>20–60 mg</td>
</tr>
<tr>
<td>Lerner et al., 1998 (50)</td>
<td>Uncontrolled treatment with behavioral therapy (including habit reversal)</td>
<td>9-week trial of behavioral therapy, including habit reversal (14 patients)</td>
<td>86</td>
<td>25.6</td>
<td>12.2</td>
<td>—</td>
</tr>
<tr>
<td>Ninan et al., 1998 (51)</td>
<td>Open-label trial</td>
<td>12-week open-label trial of venlafaxine (12 subjects)</td>
<td>83</td>
<td>38.8</td>
<td>—</td>
<td>50–375 mg</td>
</tr>
<tr>
<td>Ninan et al., 2000 (52)</td>
<td>Randomized double-blind placebo-controlled parallel design</td>
<td>9 weeks clomipramine (6 subjects) or 9 weeks placebo (5 subjects) or 9 weeks cognitive behavior therapy (5 subjects)</td>
<td>81</td>
<td>33.38</td>
<td>9.09</td>
<td>50–250 mg</td>
</tr>
<tr>
<td>Stewart and Nejtek, 2003 (53)</td>
<td>Open-label trial</td>
<td>12-week flexible dose of olanzapine (17 subjects)</td>
<td>100</td>
<td>36.8</td>
<td>12.5</td>
<td>2.5–10 mg</td>
</tr>
<tr>
<td>Van Minnen et al., 2003 (54)</td>
<td>Randomized waiting-list-controlled parallel design</td>
<td>12 weeks behavioral therapy (14 subjects) or 12 weeks fluoxetine (11 subjects) or 12 weeks on waiting list (15 subjects)</td>
<td>88</td>
<td>31.9</td>
<td>11.5</td>
<td>20–60 mg</td>
</tr>
<tr>
<td>Dougherty et al., 2006 (55)</td>
<td>Randomized dual modality versus single modality study with those who did not respond to sertraline</td>
<td>12 weeks sertraline, 10 weeks sertraline (4 subjects) or 10 weeks habit reversal therapy (9 subjects) or 10 weeks sertraline plus habit reversal therapy (11 subjects)</td>
<td>96</td>
<td>28.1</td>
<td>8.2</td>
<td>25–200 mg</td>
</tr>
<tr>
<td>Lochner et al., 2006 (56)</td>
<td>Open-label trial</td>
<td>16 weeks topiramate, flexible-dose titration (9 subjects)</td>
<td>93</td>
<td>31.6</td>
<td>8.4</td>
<td>25–250 mg</td>
</tr>
</tbody>
</table>
TABLE 1. Summary of Trichotillomania Clinical Treatment Trials, 1980–2006 (continued)

<table>
<thead>
<tr>
<th>Study Author and Year</th>
<th>Design</th>
<th>Treatment and Number of Subjects Completing Treatment</th>
<th>Percent Female</th>
<th>Age (years)</th>
<th>Titrations Range</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Woods et al., 2006 (57)</td>
<td>Randomized waiting-list-controlled parallel design</td>
<td>12 weeks combined habit reversal therapy and acceptance and commitment therapy (12 subjects) or 12 weeks on waiting list (13 subjects)</td>
<td>92</td>
<td>35</td>
<td>10.2</td>
<td>Evidence for superiority of therapy over waiting-list control condition</td>
</tr>
</tbody>
</table>

a Data on age and sex refer to participants who completed the study where available; otherwise data refer to all participants.

Clinical progress. The superiority of the SSRIs mirrors results seen in OCD, for which these agents are effective and non-SSRIs are not (see reference 59 for a review). Ninan and colleagues (52) subsequently compared the effects of 9 weeks of clomipramine treatment, placebo, and cognitive behavior therapy (including habit reversal) in a parallel randomized study. The drug and placebo conditions were double-blind, although there was no suitable control for the therapy condition. Behavioral therapy was superior to clomipramine and placebo in reducing trichotillomania symptoms as assessed by the Trichotillomania Impairment Scale and the Trichotillomania Severity Score. Patients in the clomipramine group experienced greater improvement than those in the placebo group, but this finding failed to reach statistical significance.

Three randomized controlled studies have evaluated fluoxetine. Christenson and colleagues (47) conducted a 6-week double-blind placebo-controlled study, and Streichenwein and Thornby (48) used a similar design but with a 12-week treatment period. In both studies, assessments included hair pulling diaries and counting pulled hairs. Neither study found evidence for superiority of fluoxetine over placebo. Van Minnen et al. (54) compared fluoxetine and behavioral therapy in a 12-week parallel-groups waiting-list-control design (without placebo control) using the MGH Hair pulling Scale to assess symptoms. Behavioral therapy, including stimulus control and stimulus response management techniques, was superior to the fluoxetine and waiting-list conditions, and the fluoxetine condition did not differentiate from the waiting-list condition. Woods and colleagues (57) found that 12 weeks of behavioral therapy (including habit reversal) was superior to the waiting-list-control condition in reducing scores on the MGH Hair pulling Scale and the Trichotillomania Impairment Scale.

Dual treatment with behavioral therapy and an SSRI may provide advantages over monotherapy in some cases. Dougherty and colleagues (55) examined the effects of adding habit reversal therapy for trichotillomania patients who had not responded to 12 weeks of sertraline treatment. At the end of the 22-week study, participants who received the dual treatment had superior outcomes according to scores on the MGH Hair pulling Scale and Clinical Global Impression scale compared with the monotherapy group. Other open-label trials have found significant symptom improvement with other drugs, including citalopram (an SSRI), venlafaxine (a mixed re-uptake inhibitor), topiramate (an antiepileptic with complex actions), and olanzapine (a dopamine and serotonin receptor antagonist) (49, 51, 53, 56) (see Table 1).

So far, few if any treatment trials have been sufficiently rigorous to provide strong evidence. Further substantiation of existing and novel therapies and combined treatment strategies using properly constituted randomized, controlled trials is required.

Summary and Recommendations

Trichotillomania is an underdiagnosed and underreported condition associated with significant social and functional impairment (8). The etiology and brain basis of trichotillomania remain unclear, which hampers improvements in diagnostic classification and treatment for this and related obsessive-compulsive spectrum disorders. Application of techniques from the neurosciences, including neurochemical challenge, structural and functional neuroimaging, and genetic analysis, will improve our understanding of these issues. Studies of unaffected relatives will help to elucidate the state versus trait nature of any abnormalities that are identified.

Patients actively disguise their symptoms to avoid disclosure; clinicians should be vigilant when patients present with inappropriate or unusual head coverings. Assessment requires great clinical sensitivity, as hair pulling can also affect other sites on body (including the pubic region), and patients frequently regard their behavior as shameful. A classic faux pas is to rush in and ask to examine the affected sites without first taking care to establish rapport and trust. Clinicians should bear in mind that trichotillomania frequently presents with concurrent depression and anxiety disorders. Moreover, given the link between trichotillomania and other obsessive-compulsive spectrum disorders, careful screening is necessary to ensure accurate diagnosis.

How should a patient such as Dr. D be managed? Given the limited available clinical research evidence, no formal treatment algorithm for trichotillomania can be formulated, and it is important to make patients aware of this; the patient’s choice is likely to be paramount in treatment selection. Clinical effectiveness usually depends on a balance between efficacy and tolerability. For pharmacotherapy, clomipramine (starting at 50 mg/day and titrating up to 250 mg/day as tolerated) could be considered in light of evidence from a randomized trial (46). An SSRI, such as...
citalopram (starting at 20 mg/day and titrating up to 60 mg/day as tolerated), may be preferable given the superior safety and tolerability of this drug class for related conditions, such as OCD, and the positive results reported for an open-label study with trichotillomania patients (49). A course of behavioral therapy incorporating habit reversal should also be considered (54). Treatment response may be monitored with the Psychiatric Institute Trichotillomania Scale or the MGH Hair pulling Scale, along with direct observation of the affected sites. It may be that dual treatment, using pharmacotherapy and psychotherapy, is more effective than monotherapy, at least in patients who do not respond to an SSRI in the first instance (55). We would also recommend educational material (60) and support web sites (e.g., www.trich.org) for the patient, as these can be of therapeutic value (61).

Received Oct. 23, 2006; revision received Dec. 8, 2006; accepted Dec. 11, 2006. From the Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Cambridge, U.K.; Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, U.K.; and the National Obsessive Compulsive Disorders Service, Queen Elizabeth II Hospital, Wellyn Garden City, Herts, U.K. Address correspondence and reprint requests to Dr. Chamberlain, Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Box 189, Cambridge, CB2 2QQ UK; src33@cam.ac.uk (email).

Funded by Wellcome Trust programme grant 076274/Z/04/Z to T.W. Robbins, B.J. Everitt, A.C. Roberts, and Dr. Sahakian.

CME Disclosure

Dr. Sahakian has provided consulting services to Cambridge Cognition, GlaxoSmithKline, Novartis, AstraZeneca, and Eli Lilly and holds shares of CeNeS. Dr. Fineberg has worked in a consulting capacity for Bristol-Myers Squibb, GlaxoSmithKline, and Lundbeck; has continued consulting for Servier. The other authors report no competing interests.

APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.

References